The AMO WHITESTAR Signature Pro Phacoemulsification System is a modular ophthalmic microsurgical system that facilitates anterior segment (i.e., cataract) ophthalmic surgery. The modular design allows the users to configure the system to meet their surgical requirements.

Device Description

The subject device is the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System, which is an upgrade to the primary predicate device, the AMO WHITESTAR Signature Phacoemulsification System (K111697). Key device components included in this 510(k) submission are the system console, advanced linear (four-button) foot pedal (ALP), and wireless remote control. The system console and wireless remote control of the subject device are substantially equivalent to the console and wireless remote control of the primary predicate device in K111697. The Advanced Linear foot pedal (ALP) used with the subject device is substantially equivalent to the foot pedal used with the secondary predicate device, the COMPACT INTUITIV System, cleared under K133115.

AI/ML Overview

This document is a 510(k) summary for the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System, not a clinical study report. It states that no clinical studies were deemed necessary to demonstrate safety and effectiveness. Therefore, the document does not contain the information required to answer the prompt directly as it pertains to acceptance criteria and performance data from a clinical study for this medical device.

The document focuses on demonstrating substantial equivalence to existing predicate devices (K111697 and K133115) based on non-clinical testing and technological characteristics.

However, I can extract information related to the non-clinical tests that were performed and the standards met, which serve as a form of "acceptance criteria" for regulatory clearance based on substantial equivalence.

Here's a summary of the non-clinical tests and the "performance" demonstrated by meeting these standards, presented as closely as possible to the requested format, while acknowledging the lack of clinical study data:

Acceptance Criteria and Device Performance (Based on Non-Clinical Testing for Substantial Equivalence)

Since no clinical studies were performed, the "acceptance criteria" here refer to compliance with recognized standards and successful completion of non-clinical design verification and validation testing, ensuring the device performs equivalently to its predicates. The "reported device performance" is its successful demonstration of meeting these standards and functional requirements.

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria Category	Specific Criteria / Standard Met	Reported Device Performance / Compliance
Electromechanical Safety	ANSI/AAMI/ES 60601-1: 2005 (Medical Electrical Equipment – Part 1: General Requirements for Basic Safety and Essential Performance. Amendment 1/Amendment 2)	Device passes acceptance criteria; performs as safely and effectively as the primary predicate.
Electromagnetic Compatibility (EMC)	EN/IEC 60601-1-2: 2007 (Medical Electrical Equipment – Part 1-2: General Requirements for Basic Safety and Essential Performance — Collateral Standard: Electromagnetic Compatibility – Requirements and Tests.)	Device passes acceptance criteria; performs as safely and effectively as the primary predicate.
High-Frequency Surgical Equipment Safety	EN/IEC 60601-2-2: 2009 (Medical Electrical Equipment – Part 2-2: Particular Requirements for the Basic Safety and Essential Performance of High-Frequency Surgical Equipment and High-Frequency Surgical Accessories.)	Device passes acceptance criteria; performs as safely and effectively as the primary predicate.
Software Life Cycle Processes	IEC 62304: 2006 (Medical Device Software – Software Life Cycle Processes.)	Device developed and tested in accordance with "AMO requirements and specifications" which comply with this standard.
Usability Engineering	IEC 62366: 2007 (Medical Device – Application of Usability Engineering to Medical Devices)	Device developed and tested in accordance with "AMO requirements and specifications" which comply with this standard.
Risk Management	ISO 14971: 2007 (Application of Risk Management to Medical Devices)	Device developed and tested in accordance with "AMO requirements and specifications" which comply with this standard.
Functional Equivalence	Performance in phacoemulsification, irrigation/aspiration, diathermy, and vitrectomy modes equivalent to the primary predicate device (K111697).	Passed acceptance criteria; found to perform as safely and effectively as the primary predicate device during these surgical modes.
Foot Pedal Equivalence	Performance of the Advanced Linear Foot Pedal (ALP) equivalent to the foot pedal in the secondary predicate device (K133115).	Found to perform as safely and effectively as the secondary predicate device's foot pedal.
Manufacturing Quality	Compliance with FDA and ISO quality system requirements prior to commercial release.	Preliminary system validation and verification data demonstrated that functional requirements and system specifications were met.

Summary Regarding Clinical Study Details:

2. Sample size used for the test set and the data provenance: Not applicable. No clinical test set data is provided as no clinical studies were performed. The "test set" for non-clinical studies is not specified in terms of sample size or data provenance beyond general compliance with standards.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. No clinical test set.
4. Adjudication method for the test set: Not applicable. No clinical test set.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. The device is a phacoemulsification system, not an AI or imaging diagnostic device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. This is not an AI algorithm device. Performance was established via engineering and bench testing, demonstrating equivalence to predicates.
7. The type of ground truth used: For non-clinical validation, "ground truth" would be defined by engineering specifications, validated test methods, and adherence to recognized standards. The device's performance was compared against these established technical benchmarks and the known performance characteristics of the predicate devices.
8. The sample size for the training set: Not applicable. This is not a machine learning device.
9. How the ground truth for the training set was established: Not applicable. This is not a machine learning device.

In conclusion, this 510(k) submission relied on non-clinical testing and a demonstration of substantial equivalence to already cleared predicate devices, rather than new clinical studies with defined acceptance criteria and performance metrics for direct patient outcomes.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an emblem featuring a stylized design of three human profiles facing right, layered on top of each other to create a sense of depth and unity.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

October 19, 2015

Abbott Medical Optics, Inc. % Ms. Christine Chun Senior Regulatory Affairs Specialist 1700 East St. Andrew Place Santa Ana, CA 92705

Re: K151636

Trade/Device Name: Amo Whitestar Signature Pro Phacoemulsification System. Whitestar Signature Pro Advance Linear (four-button) Foot Pedal, Whitestar Signature Pro (wireless) Remote Control Regulation Number: 21 CFR 886.4670

Regulation Name: Phacofragmentation System Regulatory Class: Class II Product Code: HQC Dated: September 11, 2015 Received: September 14, 2015

Dear Christine Chun:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"

(21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation

(21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Eric A. Mann -S

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear. Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) Unknown at this time

Device Name

AMO WHITESTAR Signature Pro Phacoemulsification System

Indications for Use (Describe)

The AMO WHITESTAR Signature Pro Phaccemulsification System is a modular ophthalmic microsurgical system that facilitates anterior segment (i.e., cataract) ophthalmic surgery. The modular design allows the users to configure the system to meet their surgical requirements.

Type of Use (Select one or both, as applicable)

☑ Repackaging (21 CFR 201.2 Subpart B)
☐ Own Use - Third Party (21 CFR 201.2 Subpart C)

X Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

6 510(k) SUMMARY

6.1 APPLICANT INFORMATION

This 510(k) summary is being submitted in accordance with the Medical Device Amendments of 1976, the requirements of the Safe Medical Devices Act (SMDA) of 1990 and 21 CFR 807.92.

Submitter Information:	Abbott Medical Optics Inc.1700 E. St. Andrew PlaceSanta Ana, CA 92705, USA
Contact Person:	Christine ChunSenior Regulatory Affairs SpecialistTel: (714) 247-8487Fax: (714) 566-3785email: christine.chun@abbott.com

Date the summary was June 12, 2015 prepared:

Subject device: Trade/Proprietary Name: AMO WHITESTAR SIGNATURE PRO Phacoemulsification System

Common/Usual Name: Cataract Extraction System

Classification Name: Phacofragmentation system (21 CFR 886.4670, Product Code HQC)

SUBSTANTIAL EQUIVALENCE SUMMARY 6.2

The AMO WHITESTAR SIGNATURE PRO Phacoemulsification System ("subject device") is an updated version of its primary predicate device, the legally marketed AMO WHITESTAR Signature Phacoemulsification System cleared in K111697 on September 27, 2011. Like its primary predicate device, the subject device is designed for use by ophthalmologists in the surgical setting to emulsify and remove a cataractous lens from the eye.

The system consists of a console that powers and operates the device, a wireless remote control, and a foot pedal. It is designed to work with phacoemulsification handpieces for phacoemulsification, irrigation, vitrectomy, and diathermy, and modular disposable tubing packs, which include fluid aspiration drainage bags, and other foot pedals. The handpieces, packs, and other foot pedals used with the subject device are the same as

{4}------------------------------------------------

those used with the primary predicate device and have been cleared in previous 510(k) filings, and are not within the scope of this premarket notification.

Abbott Medical Optics Inc. (AMO) hereby claims substantial equivalence between the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System console, remote control, and its system components with those contained in the legally-marketed AMO WHITESTAR Signature Phacoemulsification System, cleared in K111697 with the exception of an additional foot pedal accessory. The Advanced Linear Foot Pedal (ALP) used with the subject device is substantially equivalent to the foot pedal used with the legally marketed COMPACT INTUITIV system, cleared in K133115.

510(k)Number	ClearanceDate	Device	Manufacturer
AMO WHITESTAR SIGNATURE PRO Phacoemulsification System -Console
K111697	09/27/2011	AMO WHITESTAR SignaturePhacoemulsification SystemPrimary Predicate Device	Abbott MedicalOptics Inc.
AMO WHITESTAR SIGNATURE PRO Phacoemulsification System -Wireless Remote Control
K111697	09/27/2011	Remote control cleared with the AMOWHITESTAR SignaturePhacoemulsification SystemPrimary Predicate DeviceAn accessory to the AMO WHITESTARSignature Phacoemulsification System	Abbott MedicalOptics Inc.
AMO WHITESTAR SIGNATURE PRO Phacoemulsification System -Advanced Linear Foot Pedal
K133115	2/27/2014	Foot Pedal cleared with the COMPACTINTUITIV SystemSecondary Predicate DeviceAn accessory to the COMPACTINTUITIV System	Abbott MedicalOptics Inc.

Legally marketed devices to which the submitter claims equivalence:

{5}------------------------------------------------

DEVICE DESCRIPTION SUMMARY 6.3

The subject device is classified under 21 CFR 886.4670 as a "phacofragmentation system," described as an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract. Like the primary predicate device in K111697, the subject device is used to perform phacoemulsification by applying ultrasonic energy combined with the mechanical action of a vibrating phaco handpiece to the cataractous lens of the eye. The system performs four basic functions: phacofragmentation, irrigation of fluid, diathermy (bipolar), and vitrectomy. The functionality, performance, intended use, and fundamental scientific technology of the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System and its accessories are equivalent to the AMO WHITESTAR Signature Phacoemulsification System cleared in K11169. The functionality, performance, intended use, and fundamental scientific technology of the Advanced Linear Foot Pedal (APL) used with the subject device is equivalent to the foot pedal used with the legally marketed COMPACT INTUITIV system, cleared in K133115.

The intended use of the subject device is anterior segment ophthalmic surgery (cataract). which is the same as the primary predicate device. The materials, energy source, operating mechanism, fundamental scientific technology, physical properties, duration and type of contact, and intended use of the subject device are identical to those of AMO WHITESTAR Signature Phacoemulsification System's console and remote control in K111697, and the COMPACT INTUITIV System's foot pedal in K133115 for the subject device's Advanced Linear foot pedal (APL). The FDA-recognized standards used for performance testing of the subject device are equivalent to those used for the primary predicate device in K111697.

6.4 INDICATIONS FOR USE

The AMO WHITESTAR SIGNATURE PRO Phacoemulsification System is a modular ophthalmic microsurgical system that facilitates anterior segment (cataract) surgery. The modular design allows the users to configure the system to meet their surgical requirements.

TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE 6.5

The main technological characteristics of the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System include phacoemulsification, diathermy, irrigation and aspiration, and vitrectomy. These technological characteristics are the same as those in the legally marketed device, the AMO WHITESTAR Signature Phacoemulsification System (K111697).

{6}------------------------------------------------

A The Phacoemulsification mode is used to break up (emulsify) the nucleus of a lens, allowing it to be aspirated from the eye through a small incision.
The Diathermy (bipolar) mode is used to coagulate blood vessels during a surgical procedure and, in some cases, to coagulate the conjunctiva following a procedure.
A The Irrigation/Aspiration mode allows for controlled aspiration of cortical material from the eve. while maintaining intraocular stability by replacing aspirated material with a balanced salt solution. A peristaltic pump provides a predictable and stable aspiration rate. Irrigation is gravity-fed, and intraocular pressure can be regulated by adjusting the height of the balanced salt solution bottle.
The Vitrectomy mode is used to cut and remove vitreous from the anterior segment of the eye during secondary intraocular lens implantation, following vitreous loss associated with trauma, or during primary cataract surgery.

These surgery modes are equivalent to the surgery modes of the primary predicate device, the AMO WHITESTAR Signature Phacoemulsification System.

Aside from the technological characteristics, the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System is equivalent to its primary predicate device, the AMO WHITESTAR Signature Phacoemulsification System (K111697), and the Advanced Control Pedal (ALP) of the subject device is equivalent to the secondary predicate device, the foot pedal used in the COMPACT INTUITIV System (K133115), in terms of intended use, design, material, basic scientific concepts, energy source, manufacturing process, and FDArecognized standards used for performance testing. The intended use of the subject device is anterior segment ophthalmic surgery, which is the same intended use as the primary predicate device.

SUMMARY OF NON-CLINICAL TESTS 6.6

The AMO WHITESTAR SIGNATURE PRO Phacoemulsification System has undergone preliminary design verification and validation to address requirements, including electromechanical safety testing (IEC testing), and is in compliance with the applicable requirements of safety standards. The subject device passed the acceptance criteria and was found to perform as safely and effectively as the primary predicate device during the following modes of anterior segment ophthalmic surgery: phacoemulsification, irrigation/aspiration, diathermy, and vitrectory. Therefore, the subject device, including the console. ALP and wireless remote control. has similar safety, effectiveness, and performance profiles as the primary and secondary predicate devices in K111697 and K133115.

The AMO WHITESTAR SIGNATURE PRO Phacoemulsification System was developed and tested in accordance with AMO requirements and specifications, which comply with the following FDA-recognized consensus standards:

{7}------------------------------------------------

ANSI/AAMI/ES 60601-1:2005	Medical Electrical Equipment – Part 1: GeneralRequirements for Basic Safety and Essential Performance.Amendment 1/Amendment 2
EN/IEC 60601-1-2: 2007	Medical Electrical Equipment – Part 1-2: GeneralRequirements for Basic Safety and Essential Performance—Collateral Standard: Electromagnetic Compatibility –Requirements and Tests.
EN/IEC 60601-2-2: 2009	Medical Electrical Equipment – Part 2-2: ParticularRequirements for the Basic Safety and EssentialPerformance of High-Frequency Surgical Equipment andHigh-Frequency Surgical Accessories.
IEC 62304: 2006	Medical Device Software – Software Life Cycle Processes.
IEC 62366: 2007	Medical Device – Application of Usability Engineering toMedical Devices
ISO 14971: 2007	Application of Risk Management to Medical Devices

All materials coming into contact with the patient fluid path are the same as those in the primary predicate device, have been cleared in previous 510(k) filings, and are outside the scope of this premarket notification.

SUMMARY OF CLINICAL TESTS 6.7

No clinical studies were deemed necessary to determine the safety and effectiveness of the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System.

CONCLUSION 6.8

The technological characteristics that determine the functionality and performance of the subject device, the AMO WHITESTAR SIGNATURE PRO Phacoemulsification System, are substantially equivalent to those cleared under K111697 for anterior segment ophthalmic surgery. The technological characteristics that determine the functionality and performance of the Advanced Linear foot pedal designed for use with the subject device is substantially equivalent to the foot pedal cleared under K133115. The AMO WHITESTAR SIGNATURE PRO Phacoemulsification System will be manufactured in compliance with FDA and ISO quality system requirements. Preliminary system validation and verification data demonstrated that the functional requirements and system specifications were met prior to commercial release.

Regulation Number and Section

§ 886.4670 Phacofragmentation system.

(a)
Identification. A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.(b)
Classification. Class II.